Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A.

BMJ open·2021
Same author

IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans.

Clinical and experimental immunology·2021
Same author

The role of the laboratory in diagnosis and management of inhibitory antibodies in haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Effect of late prophylaxis in hemophilia on joint status: a randomized trial.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.

Journal of thrombosis and haemostasis : JTH·2017
Same journal

Prophylactic Factor Replacement Versus on-Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10-Year Follow-up.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Accuracy of Factor VIII Assays for Measuring Damoctocog Alfa Pegol: A Comparative Analysis.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Real-World Assessment of rVIII-SingleChain for Prophylactic Treatment in People With Severe Hemophilia A in High-Resource Settings.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Platelet Hyperreactivity May Contribute to Thrombotic Complications in Afibrinogenemia: A Case-Based Observation.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Predictors and Clinical Impact of Time to Diagnosis in Acquired Haemophilia A: An 11-Year Retrospective Cohort Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Inhibitor development.

J Astermark1, S Lacroix-Desmazes, M T Reding

  • 1Department for Coagulation Disorders, Malmö University Hospital, Malmö, Sweden. jan.astermark@med.lu.se

Haemophilia : the Official Journal of the World Federation of Hemophilia
|June 25, 2008
PubMed
Summary
This summary is machine-generated.

Understanding the immune response to factor VIII (FVIII) involves genetic and non-genetic factors. This review explores risk factors and the role of von Willebrand factor and T-regulatory cells in hemophilia inhibitor development.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Experiment Videos

Last Updated: Jul 4, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Area of Science:

  • Immunology
  • Genetics
  • Hematology

Background:

  • The development of inhibitory antibodies against factor VIII (FVIII) is a significant challenge in hemophilia treatment.
  • This immune response is a complex process influenced by multiple genetic and non-genetic factors.

Purpose of the Study:

  • To review current understanding of genetic and non-genetic risk factors for FVIII inhibitor development.
  • To explore the modulatory effects of von Willebrand factor (VWF) on FVIII immunogenicity.
  • To discuss the role of T-regulatory cells in inhibitor pathogenicity.

Main Methods:

  • Literature review of genetic and non-genetic risk factors.
  • Analysis of the impact of von Willebrand factor on factor VIII antigenicity.
  • Discussion of the role of T-regulatory cells in immune responses.

Main Results:

  • Multiple immune regulatory genes and cells contribute to the risk of developing FVIII inhibitors.
  • Von Willebrand factor may modulate factor VIII immunogenicity.
  • T-regulatory cells play a role in the pathogenicity of inhibitors.

Conclusions:

  • A comprehensive understanding of these factors is crucial for developing novel therapeutic strategies for hemophilia patients.
  • Further research into genetic predispositions, VWF interactions, and T-cell regulation can improve inhibitor management.